Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550849 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00550849 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 16 participants.
The verdict
NCT00550849, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study assesses the safety and tolerability of RTA 402 in patients with liver disease.
Interventions
- DRUG RTA 402
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-04-30 |
| Est. Completion | 2007-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550849
The ClinicalTrials.gov registry entry for NCT00550849 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RTA 402 is the first listed.
NCT00550849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550849 about?
NCT00550849 is a clinical study titled "Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction". This study assesses the safety and tolerability of RTA 402 in patients with liver disease.
What is the current status of trial NCT00550849?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-04-30. Estimated completion is 2007-11-30.
What interventions are being tested in trial NCT00550849?
The interventions under investigation include: RTA 402 (DRUG).
Who is sponsoring clinical trial NCT00550849?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.